RESEARCH MONOGRAPH · KDC-MN-017

Armodafinil

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

73/100

The R-enantiomer of modafinil. Slightly cleaner PK, mostly the same drug

Armodafinil is the R-(minus)-enantiomer of modafinil isolated and developed as a separate product by Cephalon (now Teva). The question worth asking is whether the enantiomeric separation produces a meaningfully different clinical compound, and the honest answer is mostly no, with some PK nuances that matter at the margin.

The pharmacokinetic profile is the cleanest argument for armodafinil. Half-life is roughly 15 hours versus 10-12 for racemic modafinil. The R-enantiomer is the longer-lived stereoisomer because the S-enantiomer is cleared faster, so isolating R gives you a flatter, more sustained plasma profile from a single morning dose. That can matter for sustained wakefulness without an afternoon trough, which is the practical clinical argument the manufacturers have made.

Pharmacodynamically, R-modafinil and S-modafinil bind DAT with similar affinity. The DAT-mediated dopamine reuptake inhibition that's central to wakefulness doesn't distinguish strongly between the enantiomers. Some of the secondary receptor activities differ between R and S, but none of these have been pinned down well enough to claim that armodafinil is mechanistically distinct from racemic modafinil in a clinically meaningful way.

Clinical evidence is solid because Cephalon repeated many of the modafinil trials with armodafinil for FDA approval purposes. Narcolepsy, OSA-related residual sleepiness, and shift-work sleep disorder all have RCT data. The effect sizes are broadly comparable to racemic modafinil. The slight half-life difference shows up in some secondary endpoints related to late-day attention.

Heres the thing thats worth saying out loud. Armodafinil as a separate product is partly a patent-life-extension strategy. That doesnt make it a bad drug, the enantiomer-selective approach is legitimate pharmacology, but the clinical advantage over racemic modafinil is modest enough that the differential pricing has been controversial.

Sourcing is fine for research-grade material from legitimate API suppliers. The synthesis to get pure R-enantiomer is non-trivial (chiral resolution or asymmetric synthesis), so vendor variability is more relevant than for the racemate; check the COA for enantiomeric excess.

Workhorse with a slightly cleaner PK story, mostly the same compound as modafinil. Treat the literature accordingly.

Evidence: 80
Mechanism: 70
Reliability: 82
Safety: 78
Sourcing: 72
Value: 60
Signal: 72
Staying power: 72

Plain-language summary Intrigue 65 / 100

Armodafinil, sold as Nuvigil, is the active half of modafinil purified out as a single enantiomer. It produces longer-lasting wakefulness than racemic modafinil because it lacks the rapidly cleared inactive enantiomer. It is FDA-approved for the same indications as modafinil. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Eugeroic / wakefulness-promoting agent (R-enantiomer)

The (R)-enantiomer of modafinil with extended duration of action and greater wakefulness-promoting potency per milligram.

Abstract

Armodafinil (CAS 112111-43-0; molecular formula C15H15NO2S; molecular weight 273.35) is the (R)-enantiomer of modafinil, marketed under the trade name Nuvigil and approved by the FDA in 2007 for the same indications as racemic modafinil. The (R)-enantiomer carries the majority of the wakefulness-promoting activity of the racemate; the (S)-enantiomer contributes a smaller fraction of the eugeroic effect and metabolizes more rapidly. Pharmacokinetics differ from racemic modafinil principally in elimination: the plasma half-life of armodafinil is 12 to 15 hours, similar to the (R)-enantiomer in racemic modafinil dosing, but absent the early peak from rapid (S)-enantiomer clearance. The result is a flatter plasma concentration curve, with sustained alertness later into the day. The research literature reports doses in the range of 150 to 250 mg. Mechanism of action mirrors that of modafinil: weak dopamine transporter binding with downstream orexinergic, histaminergic, and glutamatergic effects. The cognitive enhancement evidence base in healthy individuals overlaps with that of modafinil; the effect sizes are modest and most consistent in sleep-deprived subjects. Schedule IV in the United States. Adverse events parallel those of modafinil; rare DRESS and Stevens-Johnson syndrome cases are documented. Drug interactions through CYP3A4 induction are clinically relevant for hormonal contraception and immunosuppressants.

Mechanism of action

Same as modafinil; the (R)-enantiomer is the more potent component of the racemate.

Reported research dose ranges

Research literature reports a range of 150 to 250 mg; bioequivalent to approximately 200 to 400 mg of racemic modafinil for wakefulness endpoints.

References

Darwish M, et al. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives. Clin Drug Investig 2009.
Harsh JR, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006.
Bogan RK. Armodafinil in the treatment of excessive sleepiness. Expert Opin Pharmacother 2010.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-017

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Armodafinil

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs